6 citations
,
January 2024 in “Cancers” Antiandrogens don't help with COVID-19 and aren't recommended.
4 citations
,
November 2022 in “Frontiers in Immunology” Lung and liver macrophages protect our tissues and their dysfunction can cause various diseases.
3 citations
,
July 2025 in “Gels” Engineered protein hydrogels improve medical treatments by mimicking natural body structures.
2 citations
,
April 2025 in “Biologics” Dupilumab and ustekinumab are promising treatments for alopecia areata, showing significant hair regrowth.
1 citations
,
December 2022 in “Frontiers in Immunology” Tissue environment greatly affects the unique epigenetic makeup of regulatory T cells, which could impact autoimmune disease treatment.
April 2026 in “Antibodies” The role of antibodies in alopecia is unclear, but JAK inhibitors show promise for treatment.
Iron deficiency worsens inflammatory skin diseases by disrupting iron balance and increasing inflammation.
February 2026 in “Medicina” Hyaluronic Acid Profhilo® reduces skin inflammation and nerve-related pain in atopic dermatitis.
February 2026 in “Stem Cell Research & Therapy” Stem cell therapies show promise for hair regrowth in alopecia areata but need more research for safety and effectiveness.
Scalp microbiome in young women is mainly affected by sensitivity, sebum, and lifestyle.
November 2025 in “Journal of Clinical Medicine” Alopecia areata patients should have eye check-ups due to increased risk of eye problems.
September 2025 in “International Journal of Molecular Sciences” International guidelines for treating alopecia areata vary, focusing on different treatment options and related health issues.
July 2025 in “Nano Research” Nanotechnology can improve tissue healing by controlling immune responses.
Alopecia Areata causes hair loss and needs treatments that address both physical and emotional health.
January 2025 in “International Journal of Molecular Sciences” Psoriasis involves immune and genetic factors, and understanding these can improve treatments.
April 2024 in “International journal of molecular sciences” Alopecia areata and vitiligo share immune system dysfunction but differ in specific immune responses and affected areas.
May 2023 in “Journal of Clinical Medicine” New understanding and treatments for hair loss are improving, but more research is needed.
58 citations
,
July 2018 in “Journal of Allergy and Clinical Immunology” Alopecia areata severity is linked to increased TH1 and TH2 activity.
15 citations
,
October 2022 in “Allergy” Dupilumab treatment reduces Th2-related markers and helps hair growth in alopecia areata, showing Th2's role in the condition.
4 citations
,
January 2011 in “Journal of UOEH” Autoimmune hair loss may be linked to increased Th1 and Th17 cells and decreased Th2 cells.
2 citations
,
November 2004 in “Blood” RXRa is crucial for Th2 immune cell development and may link nutrition to immune health.
1 citations
,
April 2023 in “World Journal of Urology” Finasteride reduces some inflammation in BPH but not all.
April 2019 in “Journal of Investigative Dermatology” Targeting immune pathways like JAK/STAT may help treat frontal fibrosing alopecia.
April 2018 in “Journal of Investigative Dermatology” Both Th1 and Th2 immune responses are increased in alopecia areata, with Th2 response more strongly linked to how severe the disease is.
Gushen Shengfa pills and Wuling capsules are more effective for hair growth and sleep quality than the control treatment.
July 2024 in “Journal of Investigative Dermatology” 1 citations
,
October 2023 in “European Journal of Dermatology” Combining hair transplantation with PRP is more effective for treating hair loss than hair transplantation alone.
6 citations
,
September 2015 in “Journal of Medicinal Chemistry” The document confirms the structures of major metabolites of the CRTh2 antagonist Setipiprant and identifies minor metabolites.
65 citations
,
December 2015 in “Experimental dermatology” Corticosteroid treatment reduces inflammation and alters hair keratins in alopecia areata.
59 citations
,
September 2021 in “Journal of Allergy and Clinical Immunology” Netherton syndrome has two subtypes with shared immune traits but different allergic and immune responses, suggesting targeted treatments.